Pharmacokinetics of alendronate: An overview

International Journal of Clinical Practice, Supplement

Volumn , Issue 101, 1999, Pages 18-26

  Lin, Jiunn H ^a   Russell, Graham ^b   Gertz, Barry ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DISEASE; BONE TISSUE; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TARGETING; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE ABSORPTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PLASMA; PRIORITY JOURNAL; RAT; REVIEW; SKELETON; TISSUE DISTRIBUTION; URINARY EXCRETION; ABSORPTION; ANIMAL; ARTICLE; BONE; DOG; DRUG EFFECT; KIDNEY; METABOLISM; PROTEIN BINDING; URINE;

ABSORPTION; ALENDRONATE; ANIMALS; BONE AND BONES; DOGS; HUMANS; KIDNEY; PROTEIN BINDING; RATS; TISSUE DISTRIBUTION;

EID: 0032915483     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Fleisch H. Chemistry and mechanisms of action of diphosphonate. In: Garattini S, Ed: Bone Resorption, Metastasis and Diphosphonate. New York: Raven Press, 1985; 33-40.
2. Fleisch H. Bisphosphonates: mechanisms of action and clinical applications. In: Peck WA, Ed: Bone Mineral Research, Annual I. Amsterdam: Excerpta Medica, 1983; 319-357.
3. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
4. Sahni M, Guenther HL, Fleisch H et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004-2011.
5. Gibaldi M, Perrier D. Absorption kinetics and bioavailability. In: Gibaldi M, Perrier D, Eds: Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982; 145-198.
6. Lin JH, Duggan DE, Chen I-W et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991; 19: 926-932.
7. Lin JH, Chen I-W, Duggan DE. Effect of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992; 20: 473-478.
8. Gertz BJ, Holland SD, Kline WF et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993; 3(suppl 3): 513-516.
9. Lin JH, Chen I-W, deLuna FA. On the absorption of alendronate in rats. J Pharm Sci 1994; 83: 1741-1746.
10. Boulenc X, Marti E, Joyeux H et al. Importance of paracellular pathway for the transport of a new bisphosphonate using human Caco-2 monolayers model. Pharmacol Biochem 1993; 46: 1591-1600.
11. Twiss IM, DeWater R, DenHartigh J et al. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 1994; 83: 699-703.
12. Daley-Yates PT, Bennet R. A comparison of the pharmacokinetics of 14C-labeled APD and 99m Yc-labeled APD in the mouse. Calcif Tissue Int 1988; 43: 135-127.
13. Wingen F, Schmèhl D. Pharmacokinetics of the osteotropic disphosphonate 3-amino-1-hydroxypropane-1,1-diphosphoric acid in mammals. Arzneim-Forsch/Drug Res 1987; 37: 1037-1042.
14. Daley-Yates PT, Dodwell DJ, Pongchaidecha M et al. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastasis. Calcif Tissue Int 1991; 49: 433-435.
15. Yakatan GY, Poynor WJ, Talbert RL et at. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31: 402-410.
16. Michael WR, King WR, Wakim JM. Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972; 21: 503-515.
17. Recker RR, Saville PD. Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol 1973; 24: 580-589.
18. Gertz BJ, Holland SD, Kline WF et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58: 288-298.
19. Fogelman I, Smith L, Mazess R et al. Absorption of oral disphosphonates in normal subjects Clin Endocrinol 1986; 24: 57-62.
20. Lin JH, Chen I-W, deLuna FA. Nonlinear kinetics of alendronate: plasma protein binding and bone uptake. Drug Metab Dispos 1994; 22: 400-405.
21. Lin JH, Chen I-W, deLuna FA et al. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther 1993; 267: 670-675.
22. Wiedmer WH, Zbinden AM, Trechsel U et al. Ultrafiltrability and Chromatographic properties of pyrophosphate, 1-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylene-bisphosphonate in aqueous buffers and in human plasma. Calcif Tissue Int 1983; 35: 397-400.
23. Daley-Yates PT, Cal JC, Cockshott A et al. Plasma protein binding of ADP: role of calcium and transferrin. Chem Biol Interact 1992; 81: 79-89.
24. Fleisch H. Bone and mineral metabolism. In: Fleisch H, Ed. Bisphosphonates in Bone Diseases: From the Laboratory to the Patients. Berne: Stampfli, 1993; 8-24.
25. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast structure. J Clin Invest 1991; 88: 2095-2105.
26. Kasting BB, Francis MD. Retention of etidronate in human, dog and rat. J Bone Miner Res 1992; 7: 513-522.
27. Gocquyt V, Kline WF, Gertz BJ et al. Pharmacokinetics of intravenous alendronate. J Clin Pharm 1999 (in press).
28. Ariens EJ. Excursions in the field of SAR: a consideration of the past, the present and the future. In: Keverling Buisman JA, Ed. Biological Activity and Chemical Structure. Amsterdam: Elsevier, 1977; 1-35.
29. Ariens JA, Simonis AM. Optimalization of pharmacokinetics - an essential aspect of drug development. In: Keverling Buisman JA, Ed. Strategy in Drug Research. Amsterdam: Elsevier, 1981; 165-178.
30. Lin JH, Chen I-W, deLuna FA et al. Renal handling of alendronate in rats. An uncharacterised renal transport system. Drug Metab Dispos 1992; 20: 608-613.
31. Troehler U, Bonjour J-P, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int 1975; 8: 6-13.
32. Eriksen EF, Gundersen HJG, Melsen F et al. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Rel Res 1984; 5: 243-252.
33. Eriksen EF, Mosekilde L, Melsen F. Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle. Bone 1986; 7: 101-108.
34. Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 1984; 6: 421-428.